FIELD: pharmacology.SUBSTANCE: invention relates to formula compounds, where A can be a single bond, a double bond, O, S, NR3, C(R3)R4, CO, C(O)N(R3), N(R3)C(O) and C(R3)-(CH2)-C(R4)； m is an integer from 1 to 4； N is 0 or an integer from 1 to 4； R1 is selected from the group consisting of phenyl and 5-member heteroaryl containing one S heteroatom optionally substituted by one or more substituents selected from the group consisting of halogen atoms, (C1-C6)alkyl and (C1-C6)alkoxy； X is a physiologically acceptable anion； R2 is a group of the formula (Y), where p is 0 or an integer from 1 to 4； Q is 0 or an integer from 1 to 4； P is absent or selected from the group consisting of CO, N(R3)C(O) and C(O)N(R3)； W is selected from the group consisting of H, (C1-C10)alkoxyl, phenyl, heteroaryl optionally substituted with one or more substituents selected from the group consisting of halogen atoms, OH, oxo (=O), CO2R3, (C1-C6)alkyl, (C1-C6)alkoxyl and phenyl； wherein heteroaryl is a mono- or bicyclic ring system having from 5 to 9 ring atoms and from 1 to 3 heteroatoms selected from N, O and S； R3 and R4 are independently selected from the group consisting of H, halogen atoms, CONH2, (C1-C6)alkyl, (C1-C6)alkanoyl and (C3-C8)cycloalkyl, as selective M3 receptor antagonists, to a method for their preparation, to compositions containing them, and to their therapeutic use for treatment of a respiratory disease such as asthma and chronic obstructive pulmonary disease (COPD).EFFECT: increased composition application efficiency.14 cl, 2 tbl, 34 exИзобретение относится к соединениям формулы (I),где А может представлять собой простую связь, двойную связь, О, S, NR3, C(R3)R4, СО, C(O)N(R3), N(R3)C(O) и C(R3)-(CH2)-C(R4)； m представляет собой целое число от 1 до 4； n равно 0 или представляет собой целое число от 1 до 4； R1 выбран из группы, состоящей из фенила и 5-членного гетероарила, содержащего один гетероатом S, возможно замещенных одним или более чем одним заместителем, вы
